%0 Journal Article
%T Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures: The DOAC-NOSTOP study rationale and design.
%A Teira Calderón A
%A Chiarito M
%A Santos IA
%A Cao D
%A Vaquerizo Montilla B
%A Jurado Román A
%A Pulido Garrido P
%A Tartaglia F
%A García-García HM
%A Díez-Gil JL
%A Sanz-Sánchez J
%J Cardiovasc Revasc Med
%V 63
%N 0
%D 2024 Jun 28
%M 38307792
暂无%R 10.1016/j.carrev.2024.01.013
%X <B>BACKGROUND: </B>patients with atrial fibrillation (AF) under treatment with chronic oral anticoagulation (OAC) often require coronary angiography with or without percutaneous coronary intervention (PCI). Deciding the management of OAC during this periprocedural period requires balancing the risks of hemorrhage and thrombotic complications. Guidelines recommend an uninterrupted strategy in patients receiving Vitamin-K Antagonists (VKA). However, for patients undergoing coronary angiography or PCI while on direct oral anticoagulants (DOACs), withdrawal 12-24 h prior to the procedure is still recommended. This is based on expert opinions given the lack of evidence. Therefore, whether DOAC discontinuation prior to trans-radial coronary procedures should be the strategy of choice is a matter of debate and solid evidence is needed to guide clinical decision making.<BR><B>METHODS: </B>The DOAC-NOSTOP study is a prospective, single-arm, open-label study evaluating the safety of DOACs continuation in 200 patients undergoing transradial percutaneous coronary procedures. DOAC treatment will not be interrupted throughout the periprocedural period. Primary outcome will be Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 events, assessed at a 30-day follow-up.<BR><B>CONCLUSIONS: </B>The DOAC-NOSTOP is the first study prospectively assessing the risk of bleeding with uninterrupted DOAC in patients undergoing trans-radial percutaneous coronary procedures.